NORADRENALIN
Phase 3Small molecule
NORADRENALIN is one of 73 small molecule programs targeting Hepatorenal Syndrome. It is currently in Phase 3.
3
Indications
5
Total Trials
3
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Arginine Vasopressin
SStanford University
Phase 3
NORADRENALIN
UUniversity of Aarhus
Phase 3
Crestor
AstraZenecaPreclinical
Proamatine
TakedaPreclinical
Lexapro
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Lescol
NovartisPreclinical
Golytely
BayerPreclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infusion1 trial
Hypotension1 trial
Evaluation of Post-Induction Hypotension Treatment with PRAM Method
Active, not recruiting·—··NCT06787404·100 enrolled
Oxygenation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NORADRENALIN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Aarhus